Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kumar Prabhash

Showing results (451-460 of 469) with videos related to

Pageof 47
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2026
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)Vanita Noronha, Vijay Patil, Nandini Menon, et al.
JCO Global Oncology|November 14, 2024
Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III TrialKumar Prabhash, Chetan Deshmukh, Hemant Malhotra, et al.
JCO Global Oncology|May 22, 2025
Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study)Akhil Kapoor, Anuj Gupta, Bipinesh Sansar, et al.
Cancer Medicine|October 31, 2020
COVID-19 in cancer patients on active systemic therapy - Outcomes from LMIC scenario with an emphasis on need for active treatmentAnant Ramaswamy, Lingaraj Nayak, Nirmalya Roy Moulik, et al.
JCO Global Oncology|June 17, 2026
Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS)Akhil Kapoor, Anuj Gupta, Bipinesh Sansar, et al.
The Lancet. Global Health|August 23, 2020
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trialVijay Patil, Vanita Noronha, Sachin Babanrao Dhumal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2023
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based ChemoradiationVijay Maruti Patil, Vanita Noronha, Nandini Menon, et al.
BMJ Oncology|January 31, 2025
Under-representation of older Indian persons with cancer in clinical trialsVanita Noronha, Vijay Patil, Nandini Menon, et al.
Journal of the National Cancer Institute|September 2, 2024
Phase III randomized trial comparing neoadjuvant paclitaxel plus platinum with 5-fluorouracil plus platinum in esophageal or gastroesophageal junction squamous cell carcinomaVanita Noronha, Vijay Maruti Patil, Nandini Menon, et al.
Frontiers in Oncology|September 27, 2021
Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in IndiaJyoti Bajpai, George Abraham, Avanish P Saklani, et al.
Pageof 47

Showing results (451-460 of 469) with videos related to

Sort By:
Pageof 47
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2026
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)Vanita Noronha, Vijay Patil, Nandini Menon, et al.
JCO Global Oncology|November 14, 2024
Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III TrialKumar Prabhash, Chetan Deshmukh, Hemant Malhotra, et al.
JCO Global Oncology|May 22, 2025
Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study)Akhil Kapoor, Anuj Gupta, Bipinesh Sansar, et al.
Cancer Medicine|October 31, 2020
COVID-19 in cancer patients on active systemic therapy - Outcomes from LMIC scenario with an emphasis on need for active treatmentAnant Ramaswamy, Lingaraj Nayak, Nirmalya Roy Moulik, et al.
JCO Global Oncology|June 17, 2026
Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS)Akhil Kapoor, Anuj Gupta, Bipinesh Sansar, et al.
The Lancet. Global Health|August 23, 2020
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trialVijay Patil, Vanita Noronha, Sachin Babanrao Dhumal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2023
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based ChemoradiationVijay Maruti Patil, Vanita Noronha, Nandini Menon, et al.
BMJ Oncology|January 31, 2025
Under-representation of older Indian persons with cancer in clinical trialsVanita Noronha, Vijay Patil, Nandini Menon, et al.
Journal of the National Cancer Institute|September 2, 2024
Phase III randomized trial comparing neoadjuvant paclitaxel plus platinum with 5-fluorouracil plus platinum in esophageal or gastroesophageal junction squamous cell carcinomaVanita Noronha, Vijay Maruti Patil, Nandini Menon, et al.
Frontiers in Oncology|September 27, 2021
Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in IndiaJyoti Bajpai, George Abraham, Avanish P Saklani, et al.
Pageof 47